ReviewLife (Basel, Switzerland)2023
Impact of Immune Cells in the Tumor Microenvironment of Prostate Cancer Metastasis.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 31 citations in OpenAlex.
- Synthetic biology of oncolytic bacteria: Comparative microbial chassis and precise killing strategies.Toxicology reports · 2026Review
- Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026Review
- Macrophage-derived extracellular vesicles in the remodeling of the prostate cancer immune microenvironment and therapeutic resistance.Journal of translational medicine · 2026Review
- Cytokines IL-6, IL-10, and CCL5 Secreted by Infiltrating B Cells Promote Cell Migration of Human Prostate Cancer Cell Lines.Oncology research · 2026Article
- ITPKA promotes invasive phenotypes in clear cell renal cell carcinoma through functional modulation of PPAR signaling.American journal of cancer research · 2026Article
- A Metastasis-competent CAF Subpopulation Defined byRecent patents on anti-cancer drug discovery · 2026Article
- Integrative bulk and single-cell transcriptomics link EZH2 to immunosuppressive programs and tumor-Treg crosstalk in castration-resistant prostate cancer.Frontiers in immunology · 2026Article
- E2F1-mediated PKMYT1 upregulation promotes prostate cancer progression by inhibiting the PPAR signaling pathway.Scientific reports · 2025Article
- Maternal malnutrition induces inflammatory pathways and oxidative stress in the dorsolateral prostate of male offspring rats.Biogerontology · 2025Article
- Article
- Assessment of Immune Cell Populations in the Peripheral Blood of Patients With Metastatic Prostate Cancer.Cureus · 2025Article
- The heat of the battle: inflammation's role in prostate cancer development and inflammation-targeted therapies.Discover oncology · 2025Review
- Integrative multi-omics analysis and machine learning refine global histone modification features in prostate cancer.Frontiers in molecular biosciences · 2025Article
- Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing.Frontiers in immunology · 2025Review
- New insights into markers for distinguishing neuroendocrine prostate cancer: evidence from single-cell analysis.Frontiers in immunology · 2025Article
- Oncolytic bacteria: A revolutionary approach to cancer therapy.Open life sciences · 2025Review
- Developing prognostic models for cholesterol-related genes linked with immune infiltration in prostate cancer.Frontiers in genetics · 2025Article
- The relationship between immune cells and prostate cancer, and the mediating role of metabolites: a Mendelian randomization study.Scientific reports · 2024Article
- Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.Molecular cancer · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer is the most prevalent type of cancer in senior American men. Currently, the five-year survival rate after the initial diagnosis of prostate cancer is close to 100%. However, it is also the second leading cause of cancer death in senior men due to the dissemination of prostate cancer cells outside of the prostate causing growth in other organs, known as metastatic prostate cancer. The tumor microenvironment (TME) plays a critical role in the development, progression and metastasis of prostate cancer. One of the major components of the TME contains various types of immune cells, often recruited by cancer cells to the cancer formation areas. The interactions among prostate cancer cells and the infiltrating immune cells affect the outcome of prostate cancer. Here, we summarize the mechanisms various infiltrating immune cells use to regulate prostate cancer metastasis and possibly lead to the development of treatment strategies. Furthermore, the information here may also give rise to preventative strategies that focus on targeting the TME of prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.